Benchmark Capital Advisors’s Amgen AMGN Stock Holding History

Benchmark Capital Advisors’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,500	Closed	-$609K	–	130
2017 Q4	$609K	Hold	3,500	–	–	0.48%	58
2017 Q3	$653K	Sell	3,500 -1,500	-30%	-$266K	0.51%	53
2017 Q2	$861K	Hold	5,000	–	–	0.68%	45
2017 Q1	$820K	Sell	5,000 -8	-0.2%	-$1.33K	0.65%	46
2016 Q4	$732K	Buy	5,008 +1,000	+25%	+$151K	0.61%	47
2016 Q3	$669K	Hold	4,008	–	–	0.51%	57
2016 Q2	$610K	Buy	4,008 +2,508	+167%	+$390K	0.5%	56
2016 Q1	$225K	Hold	1,500	–	–	0.2%	100
2015 Q4	$243K	Buy	+1,500	New	+$236K	0.21%	92

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Benchmark Capital Advisors's AMGN Position: Q1 2018 in Review

Benchmark Capital Advisors sold out of Amgen (AMGN) in Q1 2018, closing a stake of 3,500 shares — an estimated $609K sold.

Benchmark Capital Advisors first reported a position in AMGN in Q4 2015 and held it in 9 quarters. The position peaked at $861K in Q2 2017. 1,750 funds tracked by Wall St. Rank hold AMGN as of Q1 2018.

Benchmark Capital Advisors reported no remaining Amgen position as of Q1 2018 after selling out during the quarter.
Benchmark Capital Advisors sold 3,500 Amgen shares in Q1 2018, an estimated $609K.
Benchmark Capital Advisors first reported a position in Amgen in Q4 2015 and held it in 9 quarters.
Benchmark Capital Advisors's Amgen position peaked at $861K in Q2 2017.
1,750 funds tracked by Wall St. Rank held Amgen as of Q1 2018.

Based on Benchmark Capital Advisors's 13F filing for Q1 2018, filed 8 May 2018.